|
Treatment (treatment period)
|
Vehicle (6.5–8)
|
ETN + PRD (6.5–8)
|
Vehicle (6.5–12)
|
ETN + PRD (6.5–12)
|
|---|
|
Both peripheral and axial disease
|
80%
|
14.3% (p = 0.01)
|
100.0%
|
62.5% (p = 0.035)
|
|
Peripheral disease only
|
0
|
14.3%
|
0.0
|
25%
|
|
Axial disease only
|
20%
|
42.9%
|
0.0
|
12.5%
|
|
Presence of axial disease
|
100%
|
57.1% (p = 0.02)
|
100.0%
|
75% (p = 0.0015)
|
|
Incidence of peripheral disease
|
80%
|
28.6%
|
100%
|
87.5%
|
|
Peripheral disease incidence at treatment commencement
|
40%
|
28.6%
|
57.1%
|
62.5%
|
|
Total number
|
5
|
7
|
7
|
8
|
- The statistical significance of data was analysed by one-tailed Z-tests compared with vehicle at corresponding time points
-
Abbreviations: ETN etanercept, PRD prednisolone
